CLDWW — Calidi Biotherapeutics, Inc.

—
NYSE · Health Care · Biotechnology · CIK 1855485 ·
Last close
—
Market Cap
—
52W High
—
52W Low
—
ADV30
—
Next earnings
—
Calidi Biotherapeutics, Inc., a biotechnology company, develops targeted therapies to deliver genetic medicines to distal sites of disease. The company offers CLD-101, which is in Phase 1b/2 clinical trial for the treatment of newly diagnosed high grade glioma, as well as in Phase 1 dose-escalation clinical trial for recurrent high-grade glioma; CLD-201 product for solid tumors, such as breast cancer, head and neck cancer, and sarcoma; and CLD-401 for the treatment of metastatic solid tumors. It also offers oncolytic virus platforms, such as NeuroNova and SuperNova. Calidi Biotherapeutics, Inc. was founded in 2014 and is headquartered in San Diego, California.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Jun 2026 0 — -4,150,000 -4,160,000 7,204,000 4,071,000 4,071,000
Mar 2026 0 — -4,187,000 -4,108,000 9,591,000 6,631,000 4,656,000
Dec 2025 0 — -4,466,000 -4,056,000 8,857,000 5,600,000 5,098,000
Sep 2025 0 — -5,048,000 -5,149,000 14,029,000 10,375,000 6,831,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-17,751,000
Investing CF
$-144,000
Financing CF
$16,808,000
CapEx
$-94,000
Dividends Paid
$0
Buybacks
—
EPS Diluted TTM
—
As of
2026-11-15

Balance + Analyst (yfinance extras)

Retained Earnings
$-149,889,000
Inventory
—
Receivables
$266,000
ST Investments
—
EBIT TTM
$-17,335,000
Pretax Income TTM
$-17,491,000
Interest Exp TTM
$156,000
Analysts
—

Annual Trend (SEC EDGAR, last 5y)

Revenues vs Net Income (last 5y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 0 -20,190,000 -19,906,000 8,857,000 5,098,000 3,759,000 -21,293,000
Dec 2024 0 -21,595,000 -22,143,000 14,182,000 12,214,000 1,534,000 -19,694,000
Dec 2023 0 -26,107,000 -29,216,000 10,019,000 18,254,000 -8,235,000 -26,983,000
Dec 2022 45,000 -23,128,000 -25,427,000 2,597,000 53,037,000 -50,440,000 -13,214,000
Dec 2021 — — — — — — —

TTM Snapshot

Revenues TTM
$-27,402,000
NetIncome TTM
$-17,397,000
OpCashFlow TTM
—
Assets (Latest)
$7,204,000
Forward EPS
—

Peers — same industry

TickerNameMarket CapLastDaily %
AMGN AMGEN INC $247.70B $457.93 —
GILD GILEAD SCIENCES, INC. $211.18B $170.26 —
MRNA Moderna, Inc. $82.56B $206.80 —
ARGX ARGENX SE $58.92B $947.52 —
BIIB BIOGEN INC. $37.07B $250.79 —

News headlines (Yahoo Finance, 1h cache)

Calidi Biotherapeutics Reports Third Quarter 2026 Financial Results and Recent Business Highlights
2026-11-13 22:03 · Yahoo
Calidi Biotherapeutics Presented New CLD-401 Data and In Situ TCE Platform Advances at the ESMO Congress 2026, Including Highlighting the Potential of its RedTail Gene Medicine Platform to Turn Tumors
2026-10-27 12:00 · Yahoo
Calidi Biotherapeutics to Present New CLD-401 Data and In Situ TCE Platform Advances at the ESMO Congress 2026
2026-10-19 12:00 · Yahoo
Calidi Biotherapeutics Received NYSE American Notification Letter Regarding Stockholders’ Equity Deficiency
2026-09-25 21:00 · Yahoo
Calidi Biotherapeutics Announces $1.2 Million Registered Direct Offering
2026-09-17 13:10 · Yahoo
Calidi Biotherapeutics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
2026-09-08 12:00 · Yahoo
Calidi Biotherapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights
2026-08-13 20:30 · Yahoo
Calidi Biotherapeutics Presents New Data on Cytotoxicity and IL-15 SA Expression in Human and Murine Tumor Cells at the American Association for Cancer Research Drug Discovery and Development Conferen
2026-07-27 12:00 · Yahoo
Calidi Biotherapeutics Provides Mid-Year Corporate Update and Future Key Value Drivers
2026-07-21 12:00 · Yahoo
Calidi Announces Reverse Stock Split, Expected to Begin Trading on a 1-for-16 Split Adjusted Basis on July 31, 2026
2026-07-20 20:30 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.